ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2057

Clinical Features of Autoimmune Uveitis and Associated Factors with Reactivation Subtype Presentation from a Peruvian Multidisciplinary Reference Center

Hugo Madariaga.Ch1, Valery Ascuña2 and RV, Gamboa-Cardenas3, and Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas , Universidad Científica del Sur, 1Clínica del Sur Sanna. Arequipa-Perú, Arequipa, Peru, 2Oftalmosalud Clinical Center. Arequipa-Perú, Arequipa, Peru, 3Universidad Científica del Sur, Lima, Lima, Peru

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Eye Disorders, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: To determine clinical features of autoimmune uveitis (AU) and the associated factors with the reactivation subtype 

Methods: A transversal analysis from single center cohort (ophthalmologic/rheumatologic outpatients’ clinic) between 2018 to 2023. Presence of AU and its clinical  subtype (acute, chronic or reactivation) were defined according with the Standardization of Uveitis Nomenclature (SUN) Project (1). Patients with at least 18 years (or with a previous parents IC in child) and with no infectious suspicious or pregnant, were included. Sociodemographic and clinical features were desfined by descriptive statistics. A multivariable binary regression model was performed to determine associated factors with AU reactivation subtype adjusted by gender, age, education, disease duration, uveitis localization, idiopathic versus secondary causes, type of autoimmune systemic disease (ASD) associated such as spondylarthritis, vasculitis -and other vessel disease, rheumatoid arthritis, and idiopathic juvenile arthritis, and the treatment prescribed [glucocorticoids (GCs) dose , GCs pulse therapy , c-DMARDs and b-DMARDs].

Results: From 459 patients, 120 were included; most patients were females 65(54.17%); Only 20 (16.67%) patients had idiopathic AU. Spondylarthritis was the most frequent ASD in the secundary AU: 49 (40.83%). Reactivation was the most frequent AU subtype :56 (46.67%). In the MV analysis variables associated with reactivation subtype were the use of intermediate/higher GCs dose (OR=26.465; p=0.001), GCs pulse therapy (OR=11.10; p=0.002) and b-DMARDs use (OR=0.040; p< 0.001) (Table 1)

Conclusion: In our AU cohort anterior uveitis and the presence of ASD (specially spondylarthritis) intead of idiophatic uveitis, were frequent. The AU reactivation subtype was associated with a more intensive treatment prescription.
(1)
Trusko B, Methods Inf Med. 2013;52(3):259-65, S1-6.

Supporting image 1


Disclosures: H. Madariaga.Ch: None; V. Ascuña: None; R. Gamboa-Cardenas: None.

To cite this abstract in AMA style:

Madariaga.Ch H, Ascuña V, Gamboa-Cardenas R. Clinical Features of Autoimmune Uveitis and Associated Factors with Reactivation Subtype Presentation from a Peruvian Multidisciplinary Reference Center [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/clinical-features-of-autoimmune-uveitis-and-associated-factors-with-reactivation-subtype-presentation-from-a-peruvian-multidisciplinary-reference-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-of-autoimmune-uveitis-and-associated-factors-with-reactivation-subtype-presentation-from-a-peruvian-multidisciplinary-reference-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology